Group 1 - The A-share market's innovative drug concept stocks have experienced a collective decline for the third consecutive day, with notable drops including Nanjing New Pharmaceutical falling over 11% and Yuandong Bio down over 9% [2] - Other companies such as Borui Pharmaceutical, Zhaoyan New Drug, and Kangyuan Pharmaceutical also saw declines exceeding 6%, while Shutaishen, Hite Bio, Shouyao Holdings, and Wanbangde dropped over 5% [2] Group 2 - The MACD golden cross signal has formed, indicating a positive trend for certain stocks [3]

（编辑 李家琪） 证券日报网讯 8月27日晚间，万邦德发布公告称，公司股票连续3个交易日内收盘价格涨幅偏离值累计 超过20%，属于股票交易异常波动。经核查，公司前期披露的信息不存在需要更正、补充之处；公司近 期经营情况正常，内外部经营环境未发生重大变化；公司控股股东及实际控制人不存在关于本公司的应 披露而未披露的重大事项。公司不存在违反信息公平披露的情形，也不存在对半年度业绩预告进行修正 的情况。 ...

证券代码：002082 证券简称：万邦德 公告编号：2025-048 万邦德医药控股集团股份有限公司 关于股票交易异常波动的公告 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共媒体报道了可能或已经对本公司股票交易价格产生较 大影响的未公开重大信息； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 万邦德医药控股集团股份有限公司（以下简称"公司"）股票连续 3 个交易 日内（2025 年 8 月 25 日，2025 年 8 月 26 日，2025 年 8 月 27 日）收盘价格涨幅 偏离值累计超过 20%，根据《深圳证券交易所交易规则》的相关规定，属于股票 交易异常波动。 二、公司关注并核实的情况 针对公司股票异常波动情况，按照相关规定的要求，公司对有关事项进行了 核查，并询问了公司控股股东及实际控制人，现就核实情况说明如下： 3、公司目前经营情况正常，不存在内外部经营环境发生重大变化的情形； 4、公司、控股股东和实际控制人不存在关于公司应披露而未披露的重大事项 或处于筹划阶段的重大事项； 5、公司控股股 ...

Market Overview - The Shanghai Composite Index fell by 0.39% on August 26, with 17 sectors rising, led by Agriculture, Forestry, Animal Husbandry, and Fishery (up 2.62%) and Beauty and Personal Care (up 2.04%) [1] - The sectors that experienced the largest declines were Pharmaceutical and Biological (down 1.09%) and Non-Bank Financials (down 1.06%) [1] - Overall, there was a net outflow of 68.855 billion yuan in the main funds across the two markets, with only two sectors seeing net inflows: Beauty and Personal Care (net inflow of 276 million yuan) and Agriculture, Forestry, Animal Husbandry, and Fishery (net inflow of 257 million yuan) [1] Pharmaceutical and Biological Sector - The Pharmaceutical and Biological sector saw a decline of 1.09%, with a net outflow of 8.254 billion yuan in main funds [2] - Out of 474 stocks in this sector, 151 stocks rose, 3 stocks hit the daily limit, and 307 stocks fell [2] - The stocks with the highest net inflows included Kangdelai (net inflow of 112 million yuan), Wanbangde (net inflow of 111 million yuan), and Anke Bio (net inflow of 80.217 million yuan) [2] - The stocks with the largest net outflows included Hanyu Pharmaceutical (net outflow of 766 million yuan), WuXi AppTec (net outflow of 706 million yuan), and Sihai Medical (net outflow of 408 million yuan) [2] Fund Flow Analysis Inflow Leaders - Kangdelai: +10.05% with a turnover rate of 10.15% and main fund flow of 111.545 million yuan [3] - Wanbangde: +9.97% with a turnover rate of 8.58% and main fund flow of 110.956 million yuan [3] - Anke Bio: -0.25% with a turnover rate of 9.03% and main fund flow of 80.217 million yuan [3] Outflow Leaders - Hanyu Pharmaceutical: -5.94% with a turnover rate of 16.12% and main fund flow of -766.138 million yuan [4] - WuXi AppTec: -3.18% with a turnover rate of 2.70% and main fund flow of -705.940 million yuan [4] - Sihai Medical: +4.99% with a turnover rate of 37.04% and main fund flow of -407.547 million yuan [4]

Market Overview - The Chinese medicine sector experienced a decline of 0.39% on August 26, with Enwei Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - ST Xiangxue: Closed at 11.74, up 12.45% with a trading volume of 532,400 shares and a turnover of 597 million yuan [1] - Wanbangde: Closed at 8.71, up 9.97% with a trading volume of 474,900 shares and a turnover of 397 million yuan [1] - Tailong Pharmaceutical: Closed at 7.24, up 5.39% with a trading volume of 541,000 shares and a turnover of 385 million yuan [1] - Conversely, Enwei Pharmaceutical saw a decline of 4.76%, closing at 37.22 with a trading volume of 32,400 shares and a turnover of 123 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 1.019 billion yuan from institutional investors, while retail investors contributed a net inflow of 764 million yuan [2] - Specific stock capital flows included: - Wanbangde: Net inflow from institutional investors of 11.5 million yuan, but net outflows from retail investors [3] - Yiling Pharmaceutical: Net inflow from institutional investors of 71.17 million yuan [3] - Tianshili: Net inflow from institutional investors of 48.64 million yuan [3]

Core Viewpoint - The company has received a patent for a cyclic peptide compound with specific disulfide bond structures, which has potential applications in various diseases and enhances drug targeting and stability [1]. Group 1: Patent Details - The patent involves a cyclic peptide compound with a specific disulfide bond structure and an efficient, controllable preparation method [1]. - The compound can precisely regulate various physiological functions through its high selectivity as a ligand for melanocortin receptors, offering new drug candidates for diseases such as neurodegenerative disorders, inflammation, autoimmune diseases, metabolic diseases, cancer, respiratory diseases, cardiovascular diseases, and reproductive system diseases [1]. - The unique structure of the compound enhances drug targeting, stability, and bioactivity, positively impacting the development of innovative drugs for conditions like Alzheimer's disease, amyotrophic lateral sclerosis, obesity, and pemphigus [1]. Group 2: Impact on the Company - The patent is not expected to have a significant immediate impact on the company's production and operations but will help protect intellectual property in new drug development [1]. - The patent will promote the company's self-research capabilities and technological innovation strength, accelerating new drug development and enhancing the company's core competitiveness [1].

Group 1 - The stock price of Wanbangde as of August 21, 2025, is 7.86 yuan, down 0.17 yuan from the previous trading day's closing price, representing a decline of 2.12% [1] - The company operates in the chemical pharmaceutical sector, with its main business segments being pharmaceutical manufacturing (48.76%), specialized equipment manufacturing and services (32.21%), and pharmaceutical distribution (15.41%) for the year 2024 [1] - Wanbangde announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., received an invention patent certificate from the National Intellectual Property Administration for a compound with specific disulfide bond structures, which could provide new drug candidates in various disease treatment areas [1] Group 2 - On August 21, 2025, the net outflow of main funds for Wanbangde was 23.04 million yuan, accounting for 0.53% of the circulating market value [1] - Over the past five days, the net inflow of main funds was 62.20 million yuan, representing 1.43% of the circulating market value [1]

证券日报网讯 8月21日晚间，万邦德发布公告称，公司全资子公司万邦德制药集团有限公司近日收到国 家知识产权局的《发明专利证书》，发明名称：一种二硫环肽化合物及其制备方法和应用。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Wanbangde Pharmaceutical Holdings Group Co., Ltd. has received a patent for a new compound and its preparation method, which may enhance its competitive edge in the pharmaceutical industry [2] - Wanbangde's revenue composition for the year 2024 is as follows: 48.76% from pharmaceutical manufacturing, 32.21% from specialized equipment manufacturing and services, 15.41% from pharmaceutical distribution, and 3.62% from other industries [2]

证券代码：002082 证券简称：万邦德 公告编号：2025-047 万邦德医药控股集团股份有限公司 关于子公司获得发明专利的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）全资子公司万邦德 制药集团有限公司近日收到国家知识产权局的《发明专利证书》，具体情况如下： | 发明名称 | 一种二硫环肽化合物及其制备方法和应用 | | --- | --- | | 专利类型 | 发明专利 | | 专利号 | ZL202411896477.2 | | 授权公告日 | 2025.8.19 | | 专利权人 | 万邦德制药集团有限公司 | 本专利涉及一种具有特定二硫键结构的环肽化合物，以及其高效、可控的制 备方法和广泛的临床应用。通过分子内二硫键形成刚性环状结构，能精准调控人 体控制多种生理功能的不同受体，其作为黑皮质素受体的高选择性配体，可在外 周或神经系统疾病、炎症、自身免疫性疾病、代谢性疾病、癌症、呼吸系统疾病、 心血管疾病、生殖系统疾病等领域治疗提供新的候选药物分子。同时，独特的结 构可提升药物的靶向性、稳定性、 ...